BGB324, also known as bemcentinib, a highly selective small molecule inhibitor of AXL, was originally developed as a cancer therapeutic target and is currently being evaluated in phase 2 trials in various cancers (NCT03184571 and NCT02872259). Here, AXL is linked to cancer.